Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CN54gp140 + GLA-AF (Imperial College London, b372ad)
- Development stage
- Phase 1
- Lead developer
- Imperial College London
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
CN54gp140 + GLA-AF is an experimental HIV-1 vaccine candidate developed by Imperial College London. It consists of a recombinant trimeric envelope protein (gp140) derived from the HIV-1 clade C strain 97CN54, formulated with the adjuvant GLA-AF (glucopyranosyl lipid adjuvant in aqueous formulation). GLA-AF is a synthetic Toll-like receptor 4 (TLR4) agonist designed to enhance the immune response. The vaccine aims to elicit both humoral (antibody) and cellular immune responses against the HIV envelope to prevent infection in healthy individuals. It has been evaluated in Phase 1 clinical trials, both as a standalone protein-adjuvant regimen and as part of heterologous prime-boost strategies involving DNA and MVA viral vectors.
- Other names
- 97CN54gp140CN54 envelope proteinCN-54 envelope proteinCN 54 envelope protein
02
Targets
FcγRII (Fc gamma receptor II)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)MYD88 (Myeloid differentiation primary response protein MyD88)TRIF (TIR-domain-containing adapter-inducing interferon-beta)gp140 (HIV-1 gp140)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on CN54gp140 + GLA-AF (Imperial College London, b372ad).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CN54gp140 + GLA-AF (Imperial College London, b372ad).